

**REMARKS**

Claims 1, 4-7, 16, 26, and 27 are currently pending in the present case. In response to the restriction requirement, claims 2, 3, 8-15, and 17-20 have been cancelled and claims 1, 4, 7, and 16 have been amended. Applicants expressly reserve the right to file divisional applications or take such other measures deemed necessary to protect the inventions in the deleted subject matter. New claims 26 and 27 have been added. The new claims and the amendments to claims 1, 4, 7, and 16 are supported by the originally filed specification and claims. No new matter has been added by way of amendment.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter  
Registration No. 45,889  
Attorney for Applicant

Date: 2/6/2008  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988